IBA SA Announces Full Year Results 2012 Date Change

IBA Announces Full Year Results 2012 Date Change

Louvain-la-Neuve, Belgium, January 24, 2013 - IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, announces today that it will issue its business update and financial results for the 2012 financial year on Monday, March 18 2013. The company was originally scheduled to announce results on March 19 2013.

IBA will host a conference call and Q&A session at 2 p.m. CET on Monday, March 18 2013. Olivier Legrain, Chief Executive Officer, and Jean-Marc Bothy, Chief Financial Officer, will host the call which will be conducted in English.  The conference call details will be included in the annual results statement to be published on March 18 at 7 a.m. CET.

- Ends -

About IBA 
IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab^® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets.  
The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact